Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial

AIMS: To investigate the safety and tolerability of 5 and 10 mg dapagliflozin added to insulin therapy over 52 weeks in Japanese patients with inadequately controlled type 1 diabetes mellitus (T1DM). MATERIALS AND METHODS: This randomized, open‐label, parallel‐group, multicentre phase III clinical t...

Descripción completa

Detalles Bibliográficos
Autores principales: Araki, Eiichi, Watada, Hirotaka, Uchigata, Yasuko, Tomonaga, Osamu, Fujii, Hitomi, Ohashi, Hiroshi, Okabe, Tadashi, Asano, Michiko, Thoren, Fredrik, Kim, Hyosung, Yajima, Toshitaka, Langkilde, Anna Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078973/
https://www.ncbi.nlm.nih.gov/pubmed/31742898
http://dx.doi.org/10.1111/dom.13922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078973/
https://www.ncbi.nlm.nih.gov/pubmed/31742898
http://dx.doi.org/10.1111/dom.13922

Ejemplares similares